{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:34:10Z","timestamp":1777109650513,"version":"3.51.4"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/leu.2017.131","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T06:41:06Z","timestamp":1493707266000},"page":"1825-1827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden"],"prefix":"10.1038","volume":"31","author":[{"given":"N","family":"Gunnarsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Stenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Dreimane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Markev\u00e4rn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Wadenvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Sj\u00e4lander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"BFleu2017131_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1667\/RR2892.1","volume":"179","author":"WL Hsu","year":"2013","unstructured":"Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950\u20132001. Radiat Res 2013; 179: 361\u2013382.","journal-title":"Radiat Res"},{"key":"BFleu2017131_CR2","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/leu.2016.59","volume":"30","author":"N Gunnarsson","year":"2016","unstructured":"Gunnarsson N, H\u00f6glund M, Stenke L, W\u00e5llberg-Jonsson S, Sandin F, Bj\u00f6rkholm M et al. Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Leukemia 2016; 30: 1562\u20131567.","journal-title":"Leukemia"},{"key":"BFleu2017131_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bjh.13346","volume":"169","author":"N Gunnarsson","year":"2015","unstructured":"Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol 2015; 169: 683\u2013688.","journal-title":"Br J Haematol"},{"key":"BFleu2017131_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/blood-2013-05-501312","volume":"122","author":"M Bjorkholm","year":"2013","unstructured":"Bjorkholm M, Kristinsson SY, Landgren O, Goldin LR . No familial aggregation in chronic myeloid leukemia. Blood 2013; 122: 460\u2013461.","journal-title":"Blood"},{"key":"BFleu2017131_CR5","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292\u20132302.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017131","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:07:16Z","timestamp":1684433236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFleu2017131"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.131","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,2]]},"assertion":[{"value":"2 May 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FS has a consulting role for Biogen. JR has received honoraria from ARIAD, Bristol-Myers Squibb, Novartis and Pfizer and received research founding from Bristol-Myers Squibb and Novartis. MB has received research founding from Adolf H Lundin Charitable Foundation. MH has a consulting role for Akinion Pharmaceuticals and Janssen-Cilag. ML has stock ownership in AstraZeneca and Pfizer. UO-S received research founding and honoraria from Bristol-Myers Squibb. The remaining authors declare no competing financial interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}